June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The PPAR-γ Agonist Troglitazone Protects RPE Cells from Oxidized LDL Induced NLRP3-inflammasome–Mediated Cell Death
Author Affiliations & Notes
  • Ashley Mackey
    Ophthalmology, Schepens Eye Research Institute/Mass Eye and Ear, Boston, Massachusetts, United States
  • Gopalan Gnanaguru
    Ophthalmology, Schepens Eye Research Institute/Mass Eye and Ear, Boston, Massachusetts, United States
  • Eun Young Choi
    Ophthalmology, Schepens Eye Research Institute/Mass Eye and Ear, Boston, Massachusetts, United States
  • Dhanesh Amarnani
    Ophthalmology, Schepens Eye Research Institute/Mass Eye and Ear, Boston, Massachusetts, United States
  • Patricia A D'Amore
    Ophthalmology, Schepens Eye Research Institute/Mass Eye and Ear, Boston, Massachusetts, United States
  • Yin Shan Eric Ng
    Ophthalmology, Schepens Eye Research Institute/Mass Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Ashley Mackey, None; Gopalan Gnanaguru, None; Eun Young Choi, None; Dhanesh Amarnani, None; Patricia D'Amore, None; Yin Shan Eric Ng, None
  • Footnotes
    Support  Grimshaw Foundation AMD Research Grant
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2288. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ashley Mackey, Gopalan Gnanaguru, Eun Young Choi, Dhanesh Amarnani, Patricia A D'Amore, Yin Shan Eric Ng; The PPAR-γ Agonist Troglitazone Protects RPE Cells from Oxidized LDL Induced NLRP3-inflammasome–Mediated Cell Death. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2288.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The retinal pigment epithelium (RPE) plays a critical role in lipid homeostasis in the retina. A growing body of evidence suggests that dysfunctional lipid metabolism, accumulation of oxidized low-density lipoprotein (ox-LDL) and inflammasome activation are associated with RPE dysfunction and the pathogenesis of dry AMD. We have previously shown that ox-LDL is cytotoxic for RPE by inflammasome-mediate pyroptosis. We hypothesize that activation of the peroxisome proliferator-activated receptors (PPARs) will increase lipid metabolism and suppress inflammation, and thereby rescue RPE cells from ox-LDL induced cell death.

Methods : ARPE-19 and/or primary human fetal RPE cells were treated for 48 hours with a range of concentrations of ox-LDL in the presence or absence of different agonists that selectively activate the three different PPAR isoforms: PPAR-α (fenofibrate 30 μM), PPAR-γ (troglitazone 0.55 μM), and PPAR-β/δ (bezafibrate 60 μM). Cell death was measured by lactate dehydrogenase release into the conditioned media. ARPE-19 cells were treated for 18 and 36 hours with ox-LDL in the presence or absence of the PPAR-γ agonist troglitazone, and fluorescent labeling with a LysoTracker probe and an anti-NF-kB antibody were used to examine lysosomal integrity and NF-kB activation by immunofluorescent staining. NLRP3-inflammasome activation was assessed by protein blot for cleaved caspase-1 and using the FAM-FLICA caspase-1 fluorescent probe assay.

Results : The PPAR-γ selective agonist troglitazone significantly protected primary human RPE and ARPE-19 cells from ox-LDL induced dysfunction and cell death, while agonists selective for the PPAR-α and PPAR-β/δ isoforms did not protect the RPE. Troglitazone protected against ox-LDL induced lysosomal destabilization and suppressed the nuclear translocation and activation of NF-kB and inflammation induced by ox-LDL. Troglitazone also suppressed activation of caspase-1, suggesting that its protective effect is mediated by inhibition of inflammasome activation.

Conclusions : The PPAR-γ selective agonist troglitazone protects RPE cells from ox-LDL–induced cell death by suppressing inflammation, preserving lysosomal integrity and ultimately preventing NLRP3-inflammasome activation. These preliminary data highlight PPAR-γ as a potential therapeutic target for protecting RPE in AMD.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×